LEXX · Lexaria Bioscience Corp.
$5.34
-0.33 (-5.82%)
At close · Aug 6
View the 10-Q filed Jul 13, 2026
Going-concern doubt
— flagged Jul 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The recurring losses and negative net cash flows raise substantial doubt as to the Company's ability to continue as a going concern.”View the 10-Q filed Jul 13, 2026
Customer concentration
— top customer 100% of revenue
One customer — 100% of revenue (nine months ended May 31, 2026)
“In the nine months ended May 31, 2026, the Company recognized revenue of $20,000 on a consolidated basis. One customer accounted for 100% of that total.”
2 customers — 100% of revenue (nine months ended May 31, 2025)
“In the nine months ended May 31, 2025, the Company recognized revenue of $531,923 on a consolidated basis. Two customers accounted for 100% of that total.”
Market Cap
$132.36M
Shares
24.79M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$5.34
Open$5.60
Day$5.33–5.74
52W$4.21–23.25
Avg vol 30d14K
Short int164K · 0.7% float · 2.8d
Short vol33%
DataJan 2021–Aug 2026
Filing10-Q · Jul 13
Up next
FQ4-26 quarter ends
~Aug 31, 2026
Est
filed Jul 13, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.2 · calm
Equity put/call 0.60
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−53%
below
Price vs 50-day avg
−37%
below
RSI (14)
33
neutral
MACD trend
Negative
52-week position
6%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−42%
trailing
6-month return
−43%
trailing
YTD return
−42%
this year
Relative strength
−54%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $8 › 200d $11 — 200d above 50d
Institutional flow
Distributing
7 of 28 funds reported for Jun 30 · net -49 sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.66% of float · ▼ -52.3% MoM · 2.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
28 holders — mid 3-yr range
Squeeze score
29
low risk · 0–100
Fundamentals
Revenue growth
+52%
Y/Y
Gross margin
100%
expanding
EPS growth
−40%
Y/Y
Free cash flow
$-10.5M
Balance sheet
$5.8M
net cash
Quant / Vol
risk profile
Volatility
111%
annualized · 1-yr
Max drawdown
−79%
past year
ATR
17.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−53%
Bearish
Price vs 50-day avg
−37%
Bearish
RSI (14)
33
Neutral
MACD trend
Negative
Bearish
52-week position
6%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $8 › 200d $11 — 200d above 50d
Institutional flow
Distributing
7 of 28 funds reported for Jun 30 · net -49 sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.66% of float · ▼ -52.3% MoM · 2.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
28 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $4
Now $5 · 6%
52-wk high $23
vs 200-day avg -53%
vs 50-day avg -37%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LEXX
this stock
Lexaria Bioscience Corp.
|
$132.36M | -42.3% | +52.0% | — | 0.7% |
|
ONC
BeOne Medicines Ltd.
|
$487.49B | +7.8% | +22179.2% | 749.6 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$122.89B | +6.9% | +46.2% | 28.2 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$79.13B | -0.2% | +20.8% | 19.0 | 3.4% |
|
ARGX
Argenx SE
|
$54.76B | +4.1% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LEXX | -10.1% | -42.1% | -42.6% | -9.0% | -42.3% |
| SPY | +5.5% | +3.3% | +11.3% | +3.1% | +12.9% |
| vs SPY | -15.6% | -45.4% | -53.8% | -12.0% | -55.2% |